The International Rare Diseases Research Consortium (IRDiRC)

GOVERNANCE

Version 6.0 June 2023
The following table lists the summary of amendments to the IRDiRC Governance document:

<table>
<thead>
<tr>
<th>Version No.</th>
<th>Date of Release</th>
<th>Approved by</th>
<th>Amendment Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Sep 2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.0</td>
<td>Feb 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.0</td>
<td>Mar 2016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.0</td>
<td>Apr 2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.0</td>
<td>Nov 2018</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 6.0         | June 2023       | Consortium Assembly on June 2023 | • Revised: Mandate of the Consortium Assembly, Operating Committee, Constituent and Scientific Committee  
• Revised: Nomination and Membership Procedure for Scientific Committees  
• Added: Regulatory Scientific Committee (RSC) to the Consortium  
• Added: 50% majority vote to reach consensus  
• Added: Working Groups  
• Added: Expected number of members of Task Forces and Working Groups  
• Added: Meetings and activity timeline of Task Forces and Working Groups |
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA</td>
<td>Consortium Assembly</td>
</tr>
<tr>
<td>CCC</td>
<td>Companies Constituent Committee</td>
</tr>
<tr>
<td>DSC</td>
<td>Diagnostics Scientific Committee</td>
</tr>
<tr>
<td>FCC</td>
<td>Funders Constituent Committee</td>
</tr>
<tr>
<td>IRDiRC</td>
<td>International Rare Diseases Research Consortium</td>
</tr>
<tr>
<td>ISC</td>
<td>Interdisciplinary Scientific Committee</td>
</tr>
<tr>
<td>LOI</td>
<td>Letter of Intent</td>
</tr>
<tr>
<td>OpComm</td>
<td>Operating Committee</td>
</tr>
<tr>
<td>PACC</td>
<td>Patient Advocates Constituent Committee</td>
</tr>
<tr>
<td>RSC</td>
<td>Regulatory Scientific Committee</td>
</tr>
<tr>
<td>SC</td>
<td>Scientific Committee</td>
</tr>
<tr>
<td>Sci Sec</td>
<td>Scientific Secretariat</td>
</tr>
<tr>
<td>TF</td>
<td>Task Forces</td>
</tr>
<tr>
<td>TSC</td>
<td>Therapies Scientific Committee</td>
</tr>
<tr>
<td>WG</td>
<td>Working Groups</td>
</tr>
</tbody>
</table>
# Table of Contents

IRDiRC Goals ......................................................................................................................... 4
IRDiRC Governance ............................................................................................................... 5
1. **Consortium Assembly (CA)** .......................................................................................... 6
   1.1 Mandate of the Consortium Assembly ............................................................................ 6
   1.2 Membership of the Consortium Assembly ........................................................................ 6
   1.3 Composition of the Consortium Assembly ...................................................................... 7
   1.4 Other Participants of the Consortium Assembly ............................................................. 8
   1.5 Meetings and Rules of Procedure of the Consortium Assembly .................................... 9
   1.6 Chair of the Consortium Assembly ............................................................................... 10
   1.7 Vice Chair of the Consortium Assembly ....................................................................... 10
2. **Operating Committee (OpComm)** ............................................................................... 11
   2.1 Mandate of the Operating Committee .......................................................................... 11
   2.2 Composition of the Operating Committee .................................................................... 11
   2.3 Meetings of the Operating Committee ......................................................................... 11
3. **Constituent Committees (CC)** ..................................................................................... 12
   3.1 Mandate of the Constituent Committees ....................................................................... 12
   3.2 Composition of the Constituent Committees ................................................................ 12
   3.3 Meetings of the Constituent Committees ...................................................................... 12
4. **Scientific Committees (SC)** .......................................................................................... 13
   4.1 Mandate of the Scientific Committees ......................................................................... 13
   4.2 Composition of the Scientific Committees .................................................................... 13
   4.3 Nomination and Membership Procedure of the Scientific Committees ...................... 14
   4.4 Meetings of the Scientific Committees ......................................................................... 15
5. **Task Forces and Working Groups** ............................................................................... 16
   5.1 Objectives of the Task Forces and Working Groups ...................................................... 16
   5.2 Mandate of the Task Forces and Working Groups ......................................................... 16
   5.3 Composition of the Task Forces and Working Groups .................................................. 16
   5.4 Meetings and Activity Timeline of Task Forces and Working Groups ....................... 17
6. **Scientific Secretariat (Sci Sec)** ...................................................................................... 18
   6.1 Mandate of the Scientific Secretariat .......................................................................... 18
   6.2 Composition of the Scientific Secretariat .................................................................... 18
**Conflict of Interest and Transparency** ............................................................................. 19

www.irdirc.org
IRDiRC Goals

The International Rare Diseases Research Consortium (IRDiRC) unites stakeholders that share a joint commitment to rare diseases research and the common principles described in this document and have agreed to work in a coordinated and collaborative manner within a multinational consortium.

At its launch in 2011, IRDiRC set two main goals to be achieved by the year 2020, namely: to deliver 200 new therapies for rare diseases, and the means to diagnose most rare diseases. These were largely accomplished by early 2017 and spurred the Consortium to establish new audacious goals for the following decade (2017-2027):

IRDiRC’s vision for the field:

- **Vision:** Enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention.

IRDiRC is committed to achieving the following three goals in the upcoming decade, through collaboration among its researchers, and organizations investing and advocating in the field of rare diseases research, in order to advance the realization of its vision for the field:

- **Goal 1:** All patients coming to medical attention with a suspected rare disease will be diagnosed within one year if their disorder is known in the medical literature; all currently undiagnosable individuals will enter a globally coordinated diagnostic and research pipeline.
- **Goal 2:** 1000 new therapies for rare diseases will be approved, the majority of which will focus on diseases without approved options.
- **Goal 3:** Methodologies will be developed to assess the impact of diagnoses and therapies on rare disease patients.
IRDiRC Governance

IRDiRC is governed through a Consortium Assembly (CA), an Operating Committee (OpComm), three Constituent Committees (CC), and four Scientific Committees (SC), aided by ad hoc Task Forces and Working Groups. The Scientific Secretariat (Sci Sec) provides organizational and communication support.

The mandate and composition of these bodies are described below.
1. **Consortium Assembly (CA)**

1.1 Mandate of the Consortium Assembly

The IRDiRC Consortium Assembly:

- Acts as the primary forum for information exchange for issues influencing IRDiRC goals and activities
- Coordinates scientific and policy efforts to address identified research priorities proposed by the Constituent and Scientific Committees, that will advance IRDiRC goals
- Adopts IRDiRC policies and guidelines
- Validates new members to the Consortium Assembly that are reviewed and recommended by the Operating Committee
- Validates new members to the Scientific Committees that are reviewed and recommended by the Operating Committee
- Validates new Task Forces and Working Groups that are reviewed and recommended by the Operating Committee
- Nominates Task Force and Working Group members
- Reviews and agrees on communication strategies that ensure timely and accurate dissemination of information regarding IRDiRC objectives and progress made

1.2 Membership of the Consortium Assembly

All membership requests must be sent in writing to the Scientific Secretariat. For IRDiRC membership consideration, the organization submits a Letter of Intent (LOI) that includes a Supporting Document stating the reasons for desiring to join IRDiRC signed by the organization’s legal representative. The Operating Committee will review membership requests and provide recommendations to the CA for validation. IRDiRC actively seeks and encourages organizations from non- or under-represented geographical regions to join due to the critical importance for IRDiRC to be representative of the global rare disease community.

The Consortium Assembly members are responsible for timely responses and transfer of information back to their organizations. To remain in good standing, Consortium Assembly members must attend/participate in at least two Consortium Assembly meetings and/or teleconferences per year. If not, the member will be notified of a 6-month probationary period, during which time the member must attend a meeting. Inactive members will be terminated and will be removed from the IRDiRC members listing and Consortium Assembly-related communications. (Also see Section 1.5: “Meetings and Rules of Procedure”)

As a condition of membership (except for umbrella organizations of patient advocacy groups), the Scientific Secretariat will collect updated information regarding funding commitment toward
IRDiRC objectives on an annual basis to ensure that member organization continue to meet the minimum commitment.

Additionally, the Scientific Secretariat will also collect, in writing, the developments at member organizations relevant to the IRDiRC mission and to the Consortium Assembly members on a biannual basis. The information provided should be non-proprietary and include 2-3 key points per year as a high-level collection of programmatic activities relevant to the IRDiRC goals and vision.

1.3 Composition of the Consortium Assembly

The IRDiRC Consortium Assembly is comprised of one representative per member funding body, group of funders (for small funders), company, umbrella patient advocacy organization, and the Chair and Vice Chair of each of the four Scientific Committees.

These individuals are approved according to the following principles:

1.3.1 Government and Non-Profit Funding Bodies
To be considered as an IRDiRC Funding member, the government and/or non-profit funding body should confirm that the organization invests or will invest in rare disease research and development (R&D) a minimum of $10 million USD (or equivalent amount in other currencies) over a five-year period (investment includes expenses associated with the organization’s internal and/or third-party RD innovation and improvements) that aligns with the goals of IRDiRC. Each government and/or non-profit funding body can nominate one representative to the Consortium Assembly, who will also serve on the Funders Constituent Committee. One alternate representative can be proposed to ensure transfer of knowledge within their organization and ensure participation in all IRDiRC meetings.

1.3.2 Group of Funders
Funding organizations that would like to contribute to IRDiRC, but which cannot reach the minimum required investment for membership on their own and/or provide funding for only a single rare disease or a subgroup of rare diseases, may form a group of funders that together reach the threshold for membership (i.e., US$10 million over a 5-year period). Each such group of funders can nominate one representative to the Consortium Assembly, who will also serve on the Funders Constituent Committee. One alternate representative can be proposed to ensure transfer of knowledge within their organization and ensure participation in all IRDiRC meetings.

1.3.3 Companies
To be considered as an IRDiRC Company member, the company should confirm that the organization invests or will invest in rare disease research and development (R&D) a minimum of $10 million USD (or equivalent amount in other currencies) over a five-year period (investment includes expenses associated with the organization’s internal and/or third-party RD innovation and improvements) that aligns with the goals of IRDiRC. Each company can nominate one
representative to the Consortium Assembly, who will also serve on the Companies Constituent Committee. One alternate representative can be proposed to ensure transfer of knowledge within their organization and ensure participation in all IRDiRC meetings.

1.3.4 Umbrella Patient Advocacy Organizations
To be considered as an IRDiRC Patient Advocacy Group member, the umbrella organization must be a patient organization (1) representing broad patients’ interests for all rare diseases in at least one country or larger area and (2) contributing to research that shares and will advance the IRDiRC vision and goals (e.g., developing and providing tools to accelerate research, diagnostic and therapeutic development, evaluation of processes). It is essential that all individuals affected by rare conditions have a voice to enhance visibility and international collaboration, and mutual exchange of knowledge and experience. In general, IRDiRC expects patient advocacy groups that are members of an umbrella organization already a member of IRDiRC to be represented appropriately by that organization within IRDiRC. Once approved, each umbrella organization can nominate one representative to the Consortium Assembly, who will also serve on the Patient Advocates Constituent Committee. IRDiRC recommends that the organization nominates a representative who has direct experience with a rare disease and has worked in the interest of patients for at least a year.

1.3.5 IRDiRC Scientific Committees
Chairs and Vice Chairs of Scientific Committees are members of the Consortium Assembly and represent their respective Scientific Committee, as a whole; each Scientific Committee gets one vote. All other Scientific Committee members are not Consortium Assembly members, but upon a proposal from a Consortium Assembly member (with a request letter submitted to the Scientific Secretariat minimum of two weeks in advance by email) may be invited as observers to its meetings. Such invitations will be issued by the Chair of the Consortium Assembly in consultation with the Operating Committee members.

1.4 Other Participants of the Consortium Assembly

1.4.1 IRDiRC Scientific Secretariat
The Scientific Secretariat is represented at Consortium Assembly meetings, except in matters in which it has, or could reasonably be perceived to have, a conflict of interest. The Scientific Secretariat representative(s) does not have voting rights at meetings of the Consortium Assembly.

1.4.2 Observers
Upon proposal from a member, the Consortium Assembly can decide to invite observers, such as representatives of regulatory bodies or learned societies, to its meetings; an observer may be given an ad hoc advisory role. Such invitations shall be issued by the Chair of the Consortium Assembly in consultation with the members of the Operating Committee. Invited observers do not have voting rights at meetings of the Consortium Assembly.
1.5 Meetings and Rules of Procedure of the Consortium Assembly

The Consortium Assembly meets at least twice a year in-person and an additional few times by teleconference (minimum of two online meetings per year). The Chair of the Consortium Assembly calls the meetings and prepares the meeting agenda with the Scientific Secretariat and input from the Operating Committee members. To remain in good standing, Consortium Assembly members must attend/participate in at least 50% of the planned meetings and/or teleconferences per year.

Consortium Assembly members represent their organizations. If a member is unavailable to attend a meeting, substituted participation by an alternate representative can be made by the authorizing person in the organization; a minimum of two weeks advance notice must be given in writing to the Chair of the Consortium Assembly and the Scientific Secretariat. During meetings, one member representative corresponds to one member organization. Alternatively, if a member cannot attend a meeting, sending comments via email beforehand in response to meeting documents will also count as participating in the meeting.

In a meeting, a quorum is present when 50% of the Consortium Assembly voting members are in attendance and participation (in person and online).

The Consortium Assembly aims to make decisions by consensus. One vote is given to each Consortium Assembly member (in person/virtually present or officially represented). A 50% majority vote must be attained to reach a consensus. If a decision cannot be reached by consensus, it is reached through a majority vote based on the number of members present at the respective meeting, assuming a quorum is present.

If a quorum cannot be reached at a meeting, or if timing is of the essence, the Chair of the Consortium Assembly may call for a vote or ask for feedback by written procedure, such as e-mail and online survey. Regardless of the method used for decision-making, a quorum comprising at least 50% of all members must respond within a maximum of 20 working days to the request for its results to be valid. If a member fails to respond within this period, their non-response is considered a “no objection”.

Unless an exception to this rule can be duly justified, all items for decision-making at any given meeting should be communicated to the Consortium Assembly members at least fourteen calendar days in advance of the meeting date. At any time, members of the Consortium Assembly, Constituent Committees, Scientific Committees, Task Forces, and Working Groups can send items to the Scientific Secretariat for the Consortium Assembly to consider and discuss.
1.6 Chair of the Consortium Assembly

The IRDiRC Consortium Assembly elects a Chair from among its members. The Chair is elected for a maximum period of three years and can be nominated for re-election to a further term, not to exceed two consecutive terms. The main responsibilities of the Chair include advancing the Consortium’s goals and activities, convening, and chairing the meetings of the Consortium Assembly and Operating Committee, and overseeing the Scientific Secretariat.

1.7 Vice Chair of the Consortium Assembly

The IRDiRC Consortium Assembly elects a Vice Chair from among its members. The Vice Chair is elected for a maximum period of three years and can be nominated for re-election to a further term, not to exceed two consecutive terms. The main responsibilities of the Vice Chair include stepping in to chair the meetings of the Consortium Assembly and Operating Committee in the absence of the Chair, and assist the Chair on requested tasks. The Vice Chair is not automatically Chair-elect; s/he may be shortlisted for the election of the Chair, alongside other candidates.
2. Operating Committee (OpComm)

The Operating Committee meets regularly to prepare and advance IRDiRC activities, process information, and enable more effective management of the consortium as a whole. The Operating Committee is not an executive decision-making body but rather the driving force to ensure alignment between Committees and successful implementation of IRDiRC Activity Roadmaps.

2.1 Mandate of the Operating Committee

The Operating Committee:

- Monitors progress of IRDiRC activities and goals
- Manages progress, processes information, and provides updates to members
- Reviews new Constituent and Scientific Committee membership applications and/or nominations, and provides propositions for the final validation by the Consortium Assembly
- Reviews Consortium Assembly meeting agendas
- Keeps the Consortium Assembly informed of all activities of the Operating Committee
- Provides a forum for resolution of any conflicts, should they arise
- Reviews IRDiRC Annual Roadmap and provides propositions for the final validation by the Consortium Assembly

2.2 Composition of the Operating Committee

The Operating Committee consists of the Chair and Vice Chair of the Consortium Assembly, the Chairs and Vice Chairs of the Constituent and Scientific Committees, and the Scientific Secretariat. The Vice Chairs of the Committees support the respective Chairs, are integral in information exchange, and attend Operating Committee meetings in the absence of the Chairs.

2.3 Meetings of the Operating Committee

The Operating Committee conducts regular teleconferences and aims to meet at a monthly interval. At any time, members of the Consortium Assembly, Constituent Committees, Scientific Committees, Task Forces, and Working Groups can send items to the Scientific Secretariat for the Operating Committee to consider and discuss.
3. **Constituent Committees (CC)**

IRDiRC has three Constituent Committees, one each for the major areas of representation – Funders, Companies, and Patient Advocates. While sharing and coordination of science and the work of scientists is central to IRDiRC goals, so are also sharing and coordination of the work of these three constituents.

### 3.1 Mandate of the Constituent Committees

The Constituent Committees:
- Act as their constituency’s coordinating body
- Identify overlap of priorities and activities, and gaps within each constituent space
- Identify common roadblocks across each constituent space worldwide
- Determine how the constituency will contribute to the goals
- Inform Consortium Assembly and other Committees of scientific and programmatic needs
- Propose Task Forces and Working Groups, publications, and other actions

### 3.2 Composition of the Constituent Committees

Each Constituent Committee is composed of Consortium Assembly members who are identified as part of that constituency. The Chair and Vice Chair of each Constituent Committee are elected by the respective Committee members and approved by the Operating Committee. The Chair and Vice Chair of each Constituent Committee are elected for a maximum period of three years and can be nominated for re-election to a further term, not to exceed two consecutive terms.

### 3.3 Meetings of the Constituent Committees

Each Constituent Committee meets in-person during the breakout sessions of Consortium Assembly in-person meetings (two in-person meetings per year). Each Constituent Committee also meets by teleconferences (minimum of two online meetings per year) convened by the Chair of the respective Constituent Committee.
4. Scientific Committees (SC)

IRDiRC has four Scientific Committees, one each for Diagnostics, Therapies, Interdisciplinary, and Regulatory aspects of rare diseases research. The Scientific Committees identify scientific and regulatory issues common to many or all members that limit the achievement of IRDiRC goals, while promulgating their findings and advising the Consortium Assembly on research priorities and progress made from a scientific and regulatory viewpoint.

4.1 Mandate of the Scientific Committees

The Scientific Committees:

- Act as scientific coordinating bodies
- Encourage exchange of protocols and best practices
- Agree on standard operating procedures, quality standards, and a roadmap to reach IRDiRC goals in their scientific area
- Report to the Consortium Assembly with regards to Committee, Task Force, and Working Group activities, and progress toward IRDiRC goals in their scientific area
- Propose research priorities for consideration by the Consortium Assembly
- Propose policies and guidelines for adoption by the Consortium Assembly
- Identify actionable projects that would advance IRDiRC goals within their focus area and bring those proposals to the Consortium Assembly
- Contribute to the establishment of Task Forces and Working Groups to advance selected projects
- Nominate members of Task Forces and Working Groups, in concert with the Consortium Assembly
- Validate and share the outcomes of Task Forces and Working Groups
- Review and approve submissions for “IRDiRC Recognized Resources”
- Address arising scientific issues within their purview
- Contribute to the preparation of annual State-of-Play report
- Contribute to the organization of scientific programs at IRDiRC conferences or IRDiRC sessions at external conferences

4.2 Composition of the Scientific Committees

Each Scientific Committee is composed of approximately 15 members with balanced geographic and expertise representation from academia, patient organizations, diagnostics, pharmaceutical industry, and regulatory bodies.

The Chair and Vice Chair of each Scientific Committee are elected by the respective Committee members and are subject to acknowledgement by the Operating Committee. The Chair and Vice Chair of each Scientific Committee are elected for an initial period of three years and can be
nominated for re-election to a further term, not to exceed two consecutive terms, and limited by the mandate of their Scientific Committee membership.

Members of the Scientific Committees are nominated for their individual expertise and are not empowered to delegate attendance at a meeting to a substitute.

Under exceptional circumstances, individual Consortium Assembly members can be nominated to also participate in a Scientific Committee under the stipulation that they are acting in their capacity as an individual scientist and not representing their organization as a whole. In cases of conflict of interest, the member must recuse him/herself from such discussions and note that to the Chair and Vice Chair of the Scientific Committee, and the Scientific Secretariat.

4.3 Nomination and Membership Procedure of the Scientific Committees

New Scientific Committee member nominations are reviewed by the respective Scientific Committee Chair, who makes recommendations to the Operating Committee for a final proposition and are validated by the Consortium Assembly. The duration of the initial mandate of the Scientific Committee members is three years with the possibility of renewal for an additional period of three years.

In the event of vacancies on the Scientific Committees, the Chairs of the Scientific Committee identify gaps of expertise and complementary areas, and consult with the Operating Committee to put forward a call for nominations. All nominations are sent in writing to the Chairs of the Scientific Committees and the Scientific Secretariat.

Candidates may be nominated by:

- Internal
  - Member organizations represented in the Consortium Assembly
  - Members of IRDiRC Scientific Committees
- External
  - Umbrella patient organizations
  - Industry associations (biotech, diagnostics, pharmaceutical, and MedTech)
  - Research organizations active in rare diseases research
  - Learned societies
  - Foundations active in the area of rare diseases
  - Self-nomination sent via email to the Scientific Secretariat or directly on the IRDiRC website

The Chairs of the Scientific Committees propose an appropriate composition of committee membership from the nominations received, ensuring member diversity and inclusion that reflects a broad global stakeholder group and is fully representative of the rare disease community. If there is no vacant position on a specific Scientific Committee at the time of a
nomination, a candidacy may be shelved or an alternative arrangement may be proposed until a position becomes available.

The mandate of a Scientific Committee member can be terminated for reason of non-participation at the discretion of the Chair of the relevant Scientific Committee. In that case, in consultation with the Chair of the Scientific Committee, the Operating Committee will decide whether a replacement appointment is necessary, and a call for nomination will be made.

A member who is unable to serve out his/her term may propose a replacement, subject to consideration among other nominees for review by the respective Scientific Committee Chairs, who will forward a recommendation to the Operating Committee for a final proposition, and validated by the Consortium Assembly.

4.4 Meetings of the Scientific Committees

Each Scientific Committee meets at least once a year in-person, and an additional few times by teleconference (with a minimum of three online meetings per year) convened by the Chair and Vice Chair of the respective Scientific Committee. Travel organization and expenses for in-person meetings are provided by the Scientific Secretariat.
5. Task Forces and Working Groups

Ad hoc, time-limited Task Forces and Working Groups are created to advance potential solutions and/or policy recommendations in specific research areas proposed by the Committees, recommended as prioritized topics by the Operating Committee, and validated by the Consortium Assembly.

5.1 Objectives of the Task Forces and Working Groups

Task Forces and Working Groups are constituted according to the following objectives:

- Topics specific to rare diseases with clear objectives and timelines
- High leverage projects with strong translational potential and international scope
- Actions for international scope and relevance
- Projects that have not been covered by other international initiatives
- Well targeted, actionable projects with potential to produce results before 2027
- Coordination with other organizations to identify gaps and needs
- Alignment and harmonization of projects with other international initiatives

5.2 Mandate of the Task Forces and Working Groups

Task Forces and Working Groups:

- Organize and contribute to topic-specific workshops
- Review and validate concept papers for their Task Force and Working Groups
- Produce and disseminate reports and publications
- Push forward implementation of Task Force and Working Group outcomes
- Develop recommendations, actions, and/or results for their Task Force or Working Group topic area(s)

5.3 Composition of the Task Forces and Working Groups

Each Task Force is composed of approximately 20 members while Working Group is composed of approximately 10 members. Members of Task Forces and Working Groups are nominated based on their specific expertise in the selected fields and include key players of diverse backgrounds (e.g. academia, industry, regulatory, advocacy) to ensure different needs are met. Joint Task Forces or Working Groups with international initiatives may include members nominated by partnering initiatives, in addition to members nominated by the IRDiRC Consortium Assembly and Committees.
5.4 Meetings and Activity Timeline of Task Forces and Working Groups

Each Task Force and Working Group meets several times through teleconference (monthly/bi-monthly, etc.) as requested by the Task Force or Working Group Chairs. Travel organization and expenses for one in-person Task Force workshop is provided by the Scientific Secretariat.

Task Forces are mandated to run their activities for a one-year period, with a possibility of three to six months extension. Working Groups are mandated to run their activities for a six-months period, with a possibility of three months extension.
6. Scientific Secretariat (Sci Sec)

The Scientific Secretariat provides organizational and communications support to IRDiRC and its members, therefore, contributing to the development of policies and guidelines aimed at accelerating research on rare diseases, reinforcing international research cooperation, and reaching IRDiRC goals.

6.1 Mandate of the Scientific Secretariat

Scientific Secretariat supports the work of IRDiRC by:

- Organizing meetings of the IRDiRC members
- Keeping members updated on IRDiRC activities and initiatives
- Providing secretarial work for the Consortium
- Conducting, upon request from and/or in direct consultation with the IRDiRC Committees, Task Forces, or Working Groups the preparation of any document necessary such as bibliographic research or synthesis on a topic
- Organizing teleconferences and workshops to advance the work of the Task Forces and Working Groups
- Collecting and diffusing pertinent information and results to the researchers funded by IRDiRC members
- Disseminating results of IRDiRC activities with various means of communication (e.g., website, newsletters, communication materials, conferences)

6.2 Composition of the Scientific Secretariat

The Scientific Secretariat is led by a Coordinator and consists of a team of staff including Project Manager(s), Information Scientist(s), Communication Manager, and Administrative Assistant.

The Scientific Secretariat reports to the Consortium Assembly and Operating Committee for its work plan and activity report. The Chairs of the Consortium Assembly oversees the Scientific Secretariat.
Conflict of Interest and Transparency

Non-Disclosure and Non-Conflict of Interest

Members of the IRDiRC Consortium Assembly and Committees shall not seek nor act in any way, either in their personal capacity or as a representative of the nominating organization, as to take undue advantage of, or exercise undue influence on, any aspects regarding the implementation of IRDiRC, including but not limited to common activities, policies, and guidelines.

Members of the IRDiRC Consortium Assembly and Committees shall inform the Chair of the Consortium Assembly, the Chair of relevant Committee (where applicable), and the Scientific Secretariat of any interests (actual or potential), which may be considered prejudicial to their role and/or their independence. Members can be requested to abstain and/or recuse from certain discussions, deliberations, or votes.

Members of the IRDiRC Consortium Assembly and Committees may participate in projects funded according to IRDiRC objectives, either in their personal capacity or as a representative of the organizations to which they belong, on the condition that such participation is disclosed. They may also participate in the evaluation or selection of proposals for funding according to IRDiRC objectives.

When a member of the IRDiRC Consortium Assembly and Committees is in breach of the requirements set out above, s/he shall be considered as no longer being in a position to continue his/her duties as a member of the group.

Transparency

Members should respect the confidential character of the discussions at the respective meetings. The names of the members of the IRDiRC Consortium Assembly and Committees are made public via the IRDiRC website. Summary reports from the Consortium Assembly meetings are published on the IRDiRC website unless the Consortium Assembly decides otherwise.